Anixa Biosciences (ANIX) director adds 2,836 shares in open-market buy

Rhea-AI Filing Summary

Anixa Biosciences director Lewis H. Titterton Jr. bought 2,836 shares of Anixa Biosciences common stock in an open-market purchase at $2.64 per share. After this transaction, he directly holds 972,170 common shares, indicating a small incremental increase in his personal stake in the company.

Insider Trade Summary

Net Buyer: 2,836 shares ($7,487)

Net Buy 1 txn

Insider Titterton Lewis H jr

Role null

Bought 2,836 shs ($7K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,836	$2.64	$7K

Holdings After Transaction: Common Stock — 972,170 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 2,836 shares Purchase price: $2.64 per share Shares owned after transaction: 972,170 shares

3 metrics

Shares purchased 2,836 shares Open-market purchase of common stock

Purchase price $2.64 per share Price paid in the reported transaction

Shares owned after transaction 972,170 shares Director’s direct holdings following the purchase

Key Terms

open-market purchase, Common Stock, Form 4

3 terms

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Titterton Lewis H jr

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE, CALIFORNIA 95118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2026		P		2,836	A	$2.64	972,170	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Lewis H. Titterton, Jr.	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Anixa Biosciences (ANIX) disclose on this Form 4?

Anixa Biosciences disclosed that director Lewis H. Titterton Jr. executed an open-market purchase of 2,836 shares of common stock. The transaction was reported on a Form 4 and reflects a direct acquisition of additional shares in the company.

At what price did the Anixa Biosciences (ANIX) director buy shares?

The director bought Anixa Biosciences common stock at a price of $2.64 per share. This reported price reflects the cost of each share in the open-market purchase disclosed in the Form 4 filing for the recent transaction.

How many Anixa Biosciences (ANIX) shares does the director own after the transaction?

Following the reported purchase, director Lewis H. Titterton Jr. directly owns 972,170 shares of Anixa Biosciences common stock. This total includes his prior holdings plus the 2,836 shares acquired in the latest open-market transaction disclosed on the Form 4.

Is the Anixa Biosciences (ANIX) insider transaction a buy or a sell?

The reported insider transaction is a buy. Director Lewis H. Titterton Jr. completed an open-market purchase of 2,836 Anixa Biosciences common shares, increasing his direct holdings according to the details disclosed in the Form 4 filing.

What type of security did the Anixa Biosciences (ANIX) director purchase?

The director purchased Anixa Biosciences common stock. The Form 4 specifies the security title as Common Stock, confirming that the insider transaction involved ordinary equity shares rather than options, warrants, or other derivative securities.